Table 6.

Overview about individuals who had reported symptoms of neuropathy following supplemental vitamin B6 intakes ≤ 100 mg/day reported in the Dutch nutrivigilance system

Dose	Cases	Latency	PLP concentrations	Symptoms, diagnosis (as reported)
100 mg/day	3 (1 M, 2 F) (2 reported by consumers, 1 by physician)	7 d, 2 y, 18 y	Reported to be above normal (2 cases), 3,266 nmol/L (exposure: 7 d)	Tingling in feed and hands, pain, neuropathy
74–75 mg/day	5 (1 M, 4 F) (all reported by consumers)	2 w, 2 m, 3 m, 16 m, 6 y	190 nmol/L (exposure: 2 m) to 2,500 nmol/L (exposure: 6 y)	Neuropathy, neurologic symptoms, pain under the feet after short walking
40–50 mg/day	5 (2 M, 3 F) (4 reported by consumers, 1 by physician)	6 m, 1 y, 2 y, 4 y, 10 y	Around 330 nmol/L (exposure; 6 m, 4 y, 10 y) to 4,338 nmol/L (exposure 2 y)	Neuropathy, numbness, paraesthesia of limbs
25–28 mg/day	5 (1 M, 4 F) (4 reported by consumers, 1 by pharmacist)	10 d, 2 m, 3 y 4 y, 6 y	88 nmol/L (exposure: 10 d) to 2,200 nmol/L (exposure: 6 y)	Neuropathy, tingling of extremities
12–21 mg/day	7 (1 M, 6 F) (6 reported by consumers, 1 by physician)	3 w, 3 m, 11 m, 1 y, 5 y, 15 y, 20 y	Reported to be above normal (2 cases), 336 nmol/L (exposure: 5 y) to 3,600 nmol/L (exposure: 11 m)	Neuropathy, nerve damage, paraesthesia, muscular weakness
5–8 mg/day	5 (5 F) (all reported by consumers)	3 m, 10 m, 1 y (2x), 15 m	Reported to be above normal (1 case), 158 nmol/L (exposure: 3 m) to 1,110 nmol/L (exposure: 15 m)	Neuropathy, paraesthesia, muscle weakness, nerve pain
1.4–3.5 mg/day	11 (3 M, 8 F) (all reported by consumers)	12 h, 1 m, 5 m, 6 m (5x), 8 m, 3 y, 23 y	Reported to be above normal (2 cases), 158 nmol/L (exposure: 6 m) to > 1,200 nmol/L (exposure: 5 m), most were in the range of 200–400 nmol/L	Neuropathy, numbness of extremities, tingling in hands, pain in hands, paraesthesia

D: days; F: female; h: hour; M: male; m: month(s); y: year(s).